A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.

@article{Mackay2005API,
  title={A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.},
  author={Helen J. Mackay and David Hedley and Pierre Major and Carol Townsley and Mary J. Mackenzie and Mark Vincent and Pam Degendorfer and Ming-Sound Tsao and Trudey Nicklee and Diana Birle and John V. Wright and Lillian L. Siu and Malcolm Moore and Amit Oza},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 15},
  pages={5526-33}
}
PURPOSE To evaluate the effects of the proteasome inhibitor bortezomib on tumor growth in patients with advanced colorectal cancer, and to explore the relationship between correlative studies and clinical outcome. DESIGN Bortezomib (1.3 mg/m(2)) was administered i.v. on days 1, 4, 8, and 11 of a 21-day cycle. Tumor response was assessed after every two cycles. Tumor biopsies were done prior to treatment and on day 9 of the first treatment cycle. Biopsies were examined for Ser(32/36)-IkappaB… CONTINUE READING